Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd.

Primary objective: To evaluate the safety and tolerability of AP025 50mg QW after multiple dosing in subjects with dyslipidemia. Secondary objectives: To evaluate the pharmacokinetic properties of AP025 50mg QW after multiple dosing in subjects with dyslipidemia. To evaluate the immunogenicity characteristics of AP025 50mg QW after multiple dosing in subjects with dyslipidemia. To evaluate the pharmacodynamic characteristics of AP025 50mg QW after multiple dosing in subjects with dyslipidemia.

Primary objectives: To evaluate the efficacy of TQA2225/AP025 in subjects with non-alcoholic steatohepatitis; Secondary objectives: To evaluate the safety of TQA2225/AP025 in subjects with non-alcoholic steatohepatitis. To evaluate the immunogenicity of TQA2225/AP025 in subjects with non-alcoholic steatohepatitis. To evaluate the pharmacokinetic (PK) characteristics of TQA2225/AP025 in subjects with non-alcoholic steatohepatitis.

Primary objective To evaluate the safety and tolerability of a single injection of different doses of AP017 monoclonal antibody injection in healthy subjects. Secondary objectives 1) To evaluate the pharmacokinetic characteristics of a single injection of different doses of AP017 monoclonal antibody injection in healthy subjects; 2) To evaluate the immunogenicity of a single injection of different doses of AP017 monoclonal antibody injection in healthy subjects; 3) To evaluate the pharmacodynamic characteristics of a single injection of different doses of AP017 monoclonal antibody injection in healthy subjects. Exploratory objective To explore the PK/PD correlation of a single injection of different doses of AP017 monoclonal antibody injection in healthy subjects.